新型冠状病毒肺炎(COVID-19)患者抗病毒用药监护的研究进展  

Progress research on pharmaceutical care of antiviral drugs for patients with corona virus disease 2019(COVID-19)

作　　者：李丹[1] 宋伟 吴杰[1] 郭咸希[1] 刘刚[1] 张如洪[2] 周本宏[1] LI Dan;SONG Wei;WU Jie;GUO Xian-xi;LIU Gang;ZHANG Ru-hong;ZHOU Ben-hong(Department of Pharmacy,Renmin Hospital of Wuhan University,Wuhan 430060,China;East District of Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院药学部,湖北武汉430060 [2]武汉大学人民医院东院,湖北武汉430060

出　　处：《现代药物与临床》2020年第4期614-619,共6页Drugs & Clinic

基　　金：国家自然科学基金资助项目(81803789、81704023、81602535);武汉大学人民医院引导基金资助项目(RMYD2018M79)

摘　　要：为提高抗病毒药物在新型冠状病毒肺炎(COVID-19)患者尤其是需要多药联合患者中的合理性和安全性,结合《新型冠状病毒肺炎诊疗方案(试行第七版)》提到的抗病毒药物,通过查阅文献、搜集各抗病毒药物说明书和MCDEX合理用药信息支持系统的相关信息,总结这些抗病毒药物的临床药动学特征、药物相互作用及不良反应信息,提出合理的用药监护建议。从药动学和药物相互作用角度加强抗病毒药物在COVID-19患者中的用药监护,可提高药物使用安全性,保障患者的合理用药。To improve the rationality and safety of anti-novel coronavirus drugs in patients with corona virus disease 2019(COVID-19),especially those with underlying diseases.Based on antiviral drugs mentioned in"COVID-19 Treatment Plan(Trial Version 7)",the clinical pharmacokinetic characteristics,drug interaction and adverse reaction information of these antiviral drugs were summarized by consulting the literature,collecting the information from the antiviral drugs instructions and the information from MCDEX rational drug use system.And the reasonable suggestions for drug monitoring were summarized and put forward.From the perspective of pharmacokinetics and drug interaction,the monitoring of antiviral drugs and combined drugs in patients with COVID-19 should be strengthened,which will be helpful for safe and rational use of these drugs.

关 键 词：新型冠状病毒肺炎 抗病毒药物 药动学 药物相互作用 药学监护 

分 类 号：R978[医药卫生—药品]